Skip to content
Menu

Elite Pharmaceuticals, Inc. ELTP

Full chart Compare
Set alert

Price alert · ELTP

All alert types
0.32 USD 0.00 (+0.00%)

Regular-session close

0.315 Day range 0.336
0.22 52-week range 0.54
YTD
-34.69%
1 year
-40.74%

Fundamental scorecard

9 of 25 checks passed on ELTP’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 3 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2023.

Value 0 of 5

  • Failed:P/E below its own 5-year median P/E 78.4 against a 5-year median of 8.3.
  • Failed:P/E under 20 P/E 78.4: an earnings yield of 1.3%.
  • Failed:Price to sales below its own 5-year median Price to sales 9.7 against a 5-year median of 2.4.
  • Failed:Price to book below its own 5-year median Price to book 11.4 against a 5-year median of 2.6.
  • Failed:Free cash flow yield above 4% Free cash flow of -4.46M is -1.3% of the market value.

Growth 2 of 5

  • Passed:Revenue grew over the last year Revenue of 35.5M is +7.8% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +35.6% a year from FY 2018 to FY 2023.
  • Failed:Earnings per share grew over the last year EPS -0.01 against 0.01 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -0.01 in FY 2018, 0.00 in FY 2023.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 3 of 5

  • Passed:Profitable over the last year Net income of 4.40M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 3 of the last 5 fiscal years.
  • Passed:Return on equity above 15% Return on equity of 15.8%.
  • Passed:Net margin above its 5-year average Net margin of 12.4% against a 5-year average of -15.4%.
  • Failed:Free cash flow is at least 80% of net income Free cash flow of -4.46M is -101.3% of net income.

Financial health 4 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 27.4M against short-term liabilities of 12.1M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 27.4M against long-term liabilities of 4.30M.
  • Passed:Net debt under 40% of equity More cash than debt: 9.08M of cash against 7.84M of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of 1.19M is 15.1% of debt.
  • Passed:Operating profit covers interest at least 3 times Operating profit is 5.9 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What ELTP owns and owes, as of Jun 30, 2023

Short term and long term

Balance sheet · 46.5M of assets

Debt, equity and cash by year

Now: 3.94M more cash than debt

Fiscal years. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

11.55 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

4 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

A+4 / 5 overall

  • DCF 4
  • Return on Equity 5
  • Return on Assets 5
  • Debt / Equity 4
  • P/E 3
  • P/B 3

Valuation

P/E 8.7×
P/S 2.6×
P/B 3.9×
P/FCF 0.0×
EV/EBITDA -566×
EV/Sales -198×
FCF Yield 5870.0%

Profitability

Gross Margin 49.4%
Operating Margin 33.6%
Net Margin 30.1%
ROE 45.4%
ROIC 32.3%
ROA 32.4%

Growth (YoY)

Revenue 77.1%
Operating Income 154.9%
EPS (diluted) 912.5%
Free Cash Flow 462778.1%

Financial Health

Current Ratio 6.4×
Quick Ratio -1216×
Debt / Equity 0.1×
Net Debt / EBITDA -573×
Interest Coverage 126×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2026-03-31